Bellus Health: BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need. Its pipeline of projects includes the Company’s lead drug candidate BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs. BLU-5937, a highly selective P2X3 antagonist, has the potential to be a best-in-class therapeutic for chronic cough patients who do not respond to current therapies.
Sector/industry:
Biotech Company / Healthcare/Biotechnology
Characteristics:
Based in...
Canada
Clinical Stage
Phase l or ll
Disease Space
Respiratory
Industry
Biotechnology
Listing
Public
Market Cap
100MM - 500MM
Therapeutic Modalities
Small Molecule
Website:
Address:
275 Armand-Frappier Boulevard
Laval, Quebec H7V 4A7
Canada

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Hamptons CEO Roundtable 2019

Bridgehampton, August 15, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.